ACCESS Newswire
16 Nov 2023, 18:35 GMT+10
ZURICH, SWITZERLAND / ACCESSWIRE / November 16, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ('NLS' or the 'Company'), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it is conducting an ongoing process to explore strategic alternatives to maximize shareholder value.
In response to the ever-evolving biotech and pharmaceutical landscape and driven by a commitment to innovation, NLS has initiated a comprehensive exploration of new opportunities that align with its core values and strengths. This strategic move aims to diversify NLS revenue streams, mitigate risks, and create lasting value for our stakeholders. As part of this process, the Company plans to consider a wide range of options with a focus on maximizing shareholder value, including strategic partnerships, out licensing assets of the Company, and other future strategic actions.
Initial steps taken:
Alex Zwyer, CEO and Co-Founder of NLS Pharmaceutics notes, 'We invite stakeholders, customers and partners to follow our journey as we explore new opportunities now and in the coming months. Regular updates and progress reports will be shared to keep everyone informed about the exciting developments stemming from this strategic exploration.'
NLS remains committed to maintaining the highest standards of quality and integrity throughout this exploration process. The Company's leadership is confident that these strategic initiatives will not only contribute to sustainable growth but also fortify our position as an emerging leader in innovative therapies for patients with rare and complex central nervous system disorders.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
Safe Harbor Statement
This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses the potential for the licensing transaction pursuant to the non-binding term sheet, the expected closing of the licensing transaction, its expected cash runway and that its leadership is confident that these strategic initiatives will not only contribute to sustainable growth but also fortify its position as an emerging leader in innovative therapies for patients with rare and complex central nervous system disorders. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading 'Risk Factors' in NLS' annual report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC), which is available on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC.
For additional information:
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
[email protected]
www.nls-pharma.com
SOURCE: NLS Pharmaceutics AG
Get a daily dose of Cleveland Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Cleveland Star.
More InformationTOKYO, Japan: Toyota is weighing plans to build the next-generation RAV4 SUV in the United States, according to three people familiar...
WASHINGTON, D.C.: Ford is recalling more than 148,000 vehicles across two safety campaigns, according to a notice issued by the National...
NEW YORK CITY, New York: Archer Aviation has announced plans to start an air-taxi service in New York City, working with United Airlines....
TAIPEI, Taiwan: Taiwan's TSMC reported stronger-than-expected first-quarter earnings on Thursday, driven by booming demand for AI-related...
LONDON - Google is facing a multibillion-pound legal challenge in the UK over allegations it misused its dominance in online search...
Lyft is making its first move into Europe with the purchase of mobility platform FreeNow, a nearly $200 million deal that signals a...
WASHINGTON, D.C.: Ford is recalling more than 148,000 vehicles across two safety campaigns, according to a notice issued by the National...
WASHINGTON, DC - A Trump administration early retirement plan at the Internal Revenue Service has been accepted by more than 22,000...
(Photo credit: Daniel Kucin Jr.-Imagn Images) Ramon Laureano homered twice Saturday in a game he wasn't expected to be so involved...
(Photo credit: Daniel Kucin Jr.-Imagn Images) Ramon Laureano homered twice Saturday in a game he wasn't expected to be so involved...
(Photo credit: Charles LeClaire-Imagn Images) Steven Kwan went 2-for-4 with an RBI and Kyle Manzardo hit a rare home run off Pirates...
(Photo credit: Troy Taormina-Imagn Images) Houston Astros rookie right fielder Cam Smith will remain under a microscope for the foreseeable...